| Research & Development
We aim to develop novel biopharmaceuticals by leveraging our exceptional scientific talent pool and developmental capabilities.
Biocon's discovery-led R&D focuses on the entire drug development pathway - from process development, to non-clinical and clinical research. The depth and breadth of our technological and scientific expertise enables us to develop new and affordable therapeutics for the world's most debilitating diseases. R&D's ability to leverage frontier science, to develop solutions for small molecules to biosimilars to novel molecules, continues to advance Biocon's reputation as an emerging global biopharma focusing on delivering affordable innovation.
Our R&D team can boast of outstanding scientists from the best institutes around the world. The high quality scientific talent pool is engaged in continuous interaction with international thought leaders and participation in technical programs to enable knowledge creation, and the positioning of Biocon's R&D for challenging biopharmaceutical development.
To navigate the challenges of innovation in the next decade we have adopted a well-defined strategic framework that will transform scientific discoveries into advances in human healthcare and generate incremental value for our shareholders.
The Innovation Matrix: A Strategic Framework
Our Innovation Matrix is a four-dimensional endeavour which extends into the realms of the known and the unknown. Creativity in the known realm builds on existing knowledge and can result in two types of innovation: INCREMENTAL and EVOLUTIONARY. Creativity that challenges unknown boundaries and creates new knowledge is EXPERIMENTAL and BREAKTHROUGH in its impact. A portfolio that covers all four spheres enables Biocon to sustain innovation in the short, medium and long term.
Our biosimilar insulin, an outcome of incremental innovation, is one of the world's most affordable therapies for insulin dependent diabetes. Bio-generic monoclonal antibodies are forming the core of our evolutionary innovation strategy. In the more challenging area of experimental innovation, Biocon is at the cutting edge. We are developing conjugated antibodies to potentially deliver therapeutic cancer vaccines. We are also pursuing a path of breakthrough innovation through global phase II human clinical trials to develop the world's first Oral Insulin. Biocon is constantly traversing the path of delivering affordable therapeutics to the patients worldwide.